Kedrion S.p.a.
Clinical trials sponsored by Kedrion S.p.a., explained in plain language.
-
New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis
Disease control TerminatedThis phase 3 study tests Coagadex, a human clotting factor X, in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops active bleeding and helps manage bleeding during surgery. Participants receive the drug on demand for bleed…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody therapy aims to shield kids with rare immune disease from deadly infections
Disease control OngoingThis study tests a medicine called Kedrion IVIG 10% in 30 children with primary immunodeficiency, a condition where the immune system doesn't work properly. The treatment is made from donated antibodies and is given through a vein to help prevent serious bacterial infections. Res…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC